Financing - May 27, 2014
Isofol raises SEK 38 million
The capital injection will be used for further clinical development of the company’s drug candidate. Modulfin is currently in phase I/II and is developed to increase the efficacy and decrease side effects during cancer treatments. It is based on a derivative of the B vitamine folic acid. At the moment, Modulfin is tested on cancer […]
Biotech Business - February 26, 2014
Index Pharmaceuticals raises EUR 15 million
Index Pharmaceuticals has announced the closing of a USD 20 million / EUR 15 million new rights issue. The Swedish biotechnology company expects to report data from a Phase III study with its lead product candidate Kappaproct, which is being developed for the treatment of severe Ulcerative Colitis. The results from the ongoing Phase III study are expected […]
Biotech Business - February 6, 2014
BerGenBio completes NOK75 million private placement
The oncology biopharmaceutical company announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. According to BerGenBio proceeds from the financing will be used to support the development of the company’s portfolio of innovative cancer […]
Financing - January 28, 2014
Genmab raises DKK 998 million in private placement
Genmab have announced that it has raised gross proceeds of DKK 998 million following pricing of its previously announced private placement. Genmab will isuue 4,600,000 new shares with a nominal value of DKK 1 each at a price of DKK 217 per share. Potential uses for the net proceeds from the transaction may include, among […]
Financing - January 24, 2014
Cantargia receives capital injection
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia has announced the conclusion of the first step in their financial plan and reinforces the board. Sven Andréasson has been appointed as chairman of the board. Sven Andréasson has extensive experience in both pharmaceutical and biotech companies. He was CEO of Active Biotech […]
Financing - November 27, 2013
Keytolead gets Vinnova funding
The start-up company Keytolead gets SEK 300 000 from the Vinnova funding program Vinn Nu. The Södertälje-based firm gets the funding to develop the work within early drug development. Keytolead runs pre-clinical research within the so-called lead generation phase. A total of 21 companies are getting funding from the program which is aimed at start-up […]
